PFS programs, Sanofi, 150m to maintain exclusivity, Hikma 175m after Rapid ramp up(?).
Biodel
ended. Depot ject unknown pharma unknown revenue unknown volumes.
AbbVie with Finesse and Lisa status unknown.
Value proposition for sale,license outsource obligations unknown.
Currently known three wearable programs Sanofi, Mefimmune, Amgem.
We await the new roadmap. RRM
- Forums
- ASX - By Stock
- UNS
- Strategic direction
Strategic direction
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online